DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase in Short Interest

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 194,600 shares, an increase of 28.4% from the November 30th total of 151,500 shares. Based on an average daily trading volume, of 87,500 shares, the days-to-cover ratio is currently 2.2 days.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of large investors have recently made changes to their positions in the business. Blue Trust Inc. purchased a new stake in DiaMedica Therapeutics in the third quarter worth $185,000. Magnolia Capital Advisors LLC bought a new position in DiaMedica Therapeutics in the 2nd quarter worth $87,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of DiaMedica Therapeutics in the 3rd quarter worth about $40,000. Finally, Geode Capital Management LLC lifted its position in shares of DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company's stock worth $1,286,000 after purchasing an additional 70,070 shares during the period. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC traded up $0.07 during mid-day trading on Friday, reaching $5.41. 132,757 shares of the company's stock traded hands, compared to its average volume of 60,697. The company has a 50 day moving average price of $4.80 and a 200-day moving average price of $4.03. The firm has a market capitalization of $231.34 million, a price-to-earnings ratio of -9.66 and a beta of 1.51. DiaMedica Therapeutics has a 12-month low of $2.14 and a 12-month high of $6.41.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.